EZH2 has been targeted pharmacologically in various tumor types with the small-molecule inhibitor GSK126 [42], a highly selective EZH2 inhibitor that competes with S-adenosyl-L-methionine binding [19]. The gene discussed is EZH2; the disease is neoplasm.